Basis of Presentation	9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation These unaudited condensed consolidated interim financial statements include the accounts of Heritage Global Inc. (“HG”) together with its subsidiaries, including Heritage Global Partners, Inc. (“HGP”), BioSurplus LLC (“BioSurplus”), National Loan Exchange Inc. (“NLEX”), Heritage Global LLC (“HG LLC”), Heritage Global Capital LLC (“HGC”), Heritage ALT LLC (“ALT”), Heritage DebtX LLC ("DebtX"), and HG Boston Note LLC (“Boston Note”). These entities, collectively, are referred to as “the Company,” “us” “we” or “our” in these condensed consolidated financial statements. These condensed consolidated financial statements were prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), as outlined in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and include the assets, liabilities, revenues, and expenses of all subsidiaries over which HG exercises control. All significant intercompany accounts and transactions have been eliminated upon consolidation. The Company began its operations in 2009 with the establishment of HG LLC. The business was subsequently expanded by the acquisitions of HGP in 2012, NLEX in 2014, ALT in 2021, DebtX and Boston Note in 2026, and the creation of HGC in 2019. As a result, HG is positioned to provide an array of value-added capital and financial asset solutions: auction and appraisal services, traditional asset disposition sales, and specialty financing solutions. As of September 30, 2026, the Company’s reportable segments consisted of (1) Auction and Liquidation through HGP and BioSurplus, (2) Refurbishment & Resale through ALT, (3) Consumer Loans through NLEX, (4) Specialty Lending through HGC, and (5) Commercial Loans through DebtX and Boston Note. On July 30, 2026, the Board of Directors (the “Board”) of the Company authorized a strategic plan (the “Exit Plan”) to wind down the Company's Specialty Lending segment. The decision followed the Board's evaluation of the segment's operating performance, risk profile and future prospects, including continued deterioration in the segment's largest borrower relationship. During the third quarter of 2026, the Company commenced implementation of the Exit Plan. The Exit Plan includes the orderly wind down of the Company's Specialty Lending operations, including the management, disposition or exit of certain joint venture investments and lending activities associated with the segment. During the wind-down period, the Company may continue to manage existing lending relationships and pursue recovery and restructuring efforts designed to maximize recoveries from the remaining portfolio. In connection with the execution of the Exit Plan, the Company has incurred and expects to incur costs associated with exit activities, consisting primarily of professional services expenses directly related to the Exit Plan. Such costs were not material for the three months ended September 30, 2026, and are not expected to be material in the aggregate. The Company will continue to incur ordinary operating expenses, primarily compensation and related costs for employees administering the wind-down of the remaining loan portfolio, which are recognized as incurred within selling, general and administrative expenses in the condensed consolidated statements of income. The Company expects the wind-down to be completed by the end of 2027, with HGC operating expenses expected to decline beginning in the first quarter. The actual timing may differ from the Company’s current estimates and will depend on the duration and scope of the activities necessary to execute the Exit Plan. The Company prepared the unaudited condensed consolidated interim financial statements included herein pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). In the opinion of management, these unaudited condensed financial statements reflect all adjustments that are necessary to present fairly the results for the interim periods included herein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are appropriate. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026 (the “Form 10-K”). The results of operations for the interim periods are not necessarily indicative of those operating results to be expected for any subsequent interim period or for the entire year ending December 31, 2026. The accompanying condensed consolidated balance sheet as of December 31, 2025 has been derived from the audited consolidated balance sheet as of December 31, 2025, contained in the Company’s Form 10-K. Repurchase Program The Board previously authorized a share repurchase program (“2022 Repurchase Program”), which permitted the Company to purchase up to an aggregate of $6.0 million in common shares over a three year period. The 2022 Repurchase Program ended on June 30, 2025, with the Company utilizing approximately $5.6 million of the authorized $6.0 million for the repurchase of 2,897,658 common shares in the open market. Following the expiration of the 2022 Repurchase Program, the Board authorized a new share repurchase program (the “2025 Repurchase Program”) on July 31, 2025. The 2025 Repurchase Program authorizes the repurchase of up to $7.5 million of the Company’s outstanding common stock through June 30, 2028. The timing and actual number of shares repurchased will depend on various factors, including share price, general business and market conditions, and the opportunities within the Company’s operations. As of September 30, 2026, the Company had approximately $7.2 million in aggregate dollar value of shares that may be purchased under the 2025 Repurchase Program.

Basis of Presentation

9 Months Ended

Sep. 30, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Note 1 – Basis of Presentation

These unaudited condensed consolidated interim financial statements include the accounts of Heritage Global Inc. (“HG”) together with its subsidiaries, including Heritage Global Partners, Inc. (“HGP”), BioSurplus LLC (“BioSurplus”), National Loan Exchange Inc. (“NLEX”), Heritage Global LLC (“HG LLC”), Heritage Global Capital LLC (“HGC”), Heritage ALT LLC (“ALT”), Heritage DebtX LLC ("DebtX"), and HG Boston Note LLC (“Boston Note”). These entities, collectively, are referred to as “the Company,” “us” “we” or “our” in these condensed consolidated financial statements. These condensed consolidated financial statements were prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), as outlined in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and include the assets, liabilities, revenues, and expenses of all subsidiaries over which HG exercises control. All significant intercompany accounts and transactions have been eliminated upon consolidation.

The Company began its operations in 2009 with the establishment of HG LLC. The business was subsequently expanded by the acquisitions of HGP in 2012, NLEX in 2014, ALT in 2021, DebtX and Boston Note in 2026, and the creation of HGC in 2019. As a result, HG is positioned to provide an array of value-added capital and financial asset solutions: auction and appraisal services, traditional asset disposition sales, and specialty financing solutions. As of September 30, 2026, the Company’s reportable segments consisted of (1) Auction and Liquidation through HGP and BioSurplus, (2) Refurbishment & Resale through ALT, (3) Consumer Loans through NLEX, (4) Specialty Lending through HGC, and (5) Commercial Loans through DebtX and Boston Note. On July 30, 2026, the Board of Directors (the “Board”) of the Company authorized a strategic plan (the “Exit Plan”) to wind down the Company's Specialty Lending segment. The decision followed the Board's evaluation of the segment's operating performance, risk profile and future prospects, including continued deterioration in the segment's largest borrower relationship.

During the third quarter of 2026, the Company commenced implementation of the Exit Plan. The Exit Plan includes the orderly wind down of the Company's Specialty Lending operations, including the management, disposition or exit of certain joint venture investments and lending activities associated with the segment. During the wind-down period, the Company may continue to manage existing lending relationships and pursue recovery and restructuring efforts designed to maximize recoveries from the remaining portfolio. In connection with the execution of the Exit Plan, the Company has incurred and expects to incur costs associated with exit activities, consisting primarily of professional services expenses directly related to the Exit Plan. Such costs were not material for the three months ended September 30, 2026, and are not expected to be material in the aggregate. The Company will continue to incur ordinary operating expenses, primarily compensation and related costs for employees administering the wind-down of the remaining loan portfolio, which are recognized as incurred within selling, general and administrative expenses in the condensed consolidated statements of income. The Company expects the wind-down to be completed by the end of 2027, with HGC operating expenses expected to decline beginning in the first quarter. The actual timing may differ from the Company’s current estimates and will depend on the duration and scope of the activities necessary to execute the Exit Plan.

The Company prepared the unaudited condensed consolidated interim financial statements included herein pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). In the opinion of management, these unaudited condensed financial statements reflect all adjustments that are necessary to present fairly the results for the interim periods included herein. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are appropriate. These unaudited condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026 (the “Form 10-K”).

The results of operations for the interim periods are not necessarily indicative of those operating results to be expected for any subsequent interim period or for the entire year ending December 31, 2026. The accompanying condensed consolidated balance sheet as of December 31, 2025 has been derived from the audited consolidated balance sheet as of December 31, 2025, contained in the Company’s Form 10-K.

Repurchase Program

The Board previously authorized a share repurchase program (“2022 Repurchase Program”), which permitted the Company to purchase up to an aggregate of $6.0 million in common shares over a three year period. The 2022 Repurchase Program ended on June 30, 2025, with the Company utilizing approximately $5.6 million of the authorized $6.0 million for the repurchase of 2,897,658 common shares in the open market.

Following the expiration of the 2022 Repurchase Program, the Board authorized a new share repurchase program (the “2025 Repurchase Program”) on July 31, 2025. The 2025 Repurchase Program authorizes the repurchase of up to $7.5 million of the Company’s outstanding common stock through June 30, 2028. The timing and actual number of shares repurchased will depend on various factors, including share price, general business and market conditions, and the opportunities within the Company’s operations. As of September 30, 2026, the Company had approximately $7.2 million in aggregate dollar value of shares that may be purchased under the 2025 Repurchase Program.